Effexor Will Rebound After “Cloud” Over Antidepressant Class Lifts, Wyeth Says
This article was originally published in The Pink Sheet Daily
Antidepressant growth has stalled amid publicity surrounding pediatric safety data, Wyeth acknowledges. Company still expects Effexor to top $3 bil. this year, helped by strong international sales.
You may also be interested in...
The congressional investigation into antidepressants could renew interest in how off-label promotion is regulated in the U.S
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.